<DOC>
	<DOCNO>NCT02049021</DOCNO>
	<brief_summary>Introduction : In spite recent advance schizophrenia treatment , 30 % patient still respond properly antipsychotic therapy . These patient consider treatment-resistant refractory , best choice clozapine . However , even support literature best know antipsychotic term efficacy rate response , considerable number patient still respond treatment , remain symptomatic dysfunctional . These patient classify super-refractory ( clozapine-resistent ) . In case , augment strategy necessary , use : typical atypical antipsychotic , mood stabilizer , antidepressant electroconvulsive therapy ( ECT ) . Some study favor ECT , definitive conclusion drawn . Objective : Test electroconvulsive therapy efficacy safety augment strategy clozapine-resistant patient , compare placebo ( sham ECT ) . Methods : This pilot double blind , placebo control randomize study assess electroconvulsive therapy efficacy augment strategy clozapine super-refractory schizophrenia . The ECT treatment deliver either MECTA SPECTRUM 5000Q 4000Q device , procedure general anesthesia monitorization , informed consent . The Hospital follow national protocol regulation ECT . Sham ECT consist habitual patient preparation sedation , without stimulation . Patients fit inclusion criterion clozapine blood level dose undergo structured assessment baseline , 6 treatment end cycle 12 ECT session ( thrice week protocol ) . The assessment base CGI ( Clinical Global Impression ) PANSS ( Positive Negative Syndrome Scale ) scale . All medication maintain , except lithium carbonate .</brief_summary>
	<brief_title>Electroconvulsive Therapy ( ECT ) Patients With Super Refractory Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<criteria>Clinical diagnosis schizophrenia schizoaffective disorder ( DSMIVTR ) ; Ages 18 55 year old , gender ; Must use adequate contraception fertile woman ; Must clozapine treatment least 6 month , without augment strategy ; Must clozapineresistent ( superrefractory patient ) , define CGIseverity ≥ 4 , PANSS total score ≥ 60 least 4 item positive subscale ≥ 4 baseline . Clinical somatic disease stabilize three month precede study ; Other Axis I disorder ( DSMIVTR ) ; Laboratory test significantly abnormal value persist two week ; Lack permanent residence study period ; History poor treatment adherence . History ECT use past six month precede start study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>electroconvulsive therapy</keyword>
	<keyword>refractory Schizophrenia</keyword>
	<keyword>super refractory schizophrenia</keyword>
	<keyword>clozapine</keyword>
</DOC>